Nationalisation of the GMO cultivation could set negative precedent for the EU single market

19.06.2014

Research Europe Magazine

In a statement issued when the deal was floated earlier this month, EuropaBio declared that any crop that meets the EU’s scientific safety requirements should be authorised “without undue delay”.  “Not so many products are left in the system. About half were withdrawn last year, so I think we have eight or nine left,” says Beat Späth, director of agricultural biotechnology at EuropaBio. He says the measures are unlikely to have much effect on the industry—and takes issue with the precedent it could set. “Essentially what is changing is that they are trying to legalise product bans that are based not on real concerns but on the general mood.”

The full article is available here under the title Growing Pains (with subscription).

Tags: